+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Edema Therapeutics Market by Type and Geography - Forecast and Analysis 2019-2023 - Product Image

Pulmonary Edema Therapeutics Market by Type and Geography - Forecast and Analysis 2019-2023

  • ID: 4849303
  • Report
  • 153 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Pulmonary Edema Therapeutics Market: About this market
The pulmonary edema therapeutics market analysis considers sales from cardiogenic pulmonary edema and non-cardiogenic pulmonary edema types. Our study also finds the sales of pulmonary edema therapeutics in Asia, Europe, North America, and ROW. In 2018, the cardiogenic pulmonary edema segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension will play a significant role in the cardiogenic pulmonary edema segment to maintain its market position. Also, our global pulmonary edema therapeutics market report looks at factors such as high prevalence of risk factors, increasing geriatric population, and growing awareness about pulmonary edema. However, adverse effects of available therapeutics, high level of genericization in the market, and availability of substitutes may hamper the growth of the pulmonary edema therapeutics industry over the forecast period.

Global Pulmonary Edema Therapeutics Market: Overview

High prevalence of risk factors
Pulmonary edema is one of the leading causes of death in adults living in developing countries. The high incidence of pulmonary edema is mainly attributed to the availability of high-risk factors such as infections, organ failures, lifestyle habits, trauma, and high altitude. Pulmonary edema can also be caused due to the potential overdosage of drugs such as aspirin and chemotherapy drugs. This high prevalence of risk factors will lead to the expansion of the global pulmonary edema therapeutics market at a CAGR of almost 3% during the forecast period.

Increasing the use of biomarkers for disease diagnosis
The detection of pulmonary edema through biomarkers is gaining prominence in recent diagnostic evaluations. A biomarker is a measurable indicator of a specific biological state or condition, including a pathogenic process. Pulmonary edema is diagnosed by clinical evaluation and imaging tests, which are the most common methods. Blood tests also play a crucial role in identifying the disease through biomarkers present in the blood. The use of biomarkers is less expensive than other evaluation tests. Moreover, these makers can detect other heart or kidney-related diseases. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global pulmonary edema therapeutics market is moderately fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary edema therapeutics manufacturers, that include AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Also, the pulmonary edema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Cardiogenic pulmonary edema - Market size and forecast 2018-2023
  • Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing use of biomarkers for disease diagnosis
  • Strategic alliances
  • Increase in funding for research on respiratory diseases
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Bausch Health Companies, Inc.
  • Johnson & Johnson Services Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AbbVie Inc. - Vendor overview
Exhibit 49: AbbVie Inc. - Business segments
Exhibit 50: AbbVie Inc. - Organizational developments
Exhibit 51: AbbVie Inc. - Geographic focus
Exhibit 52: AbbVie Inc. - Key offerings
Exhibit 53: AbbVie Inc. - Key customers
Exhibit 54: Bausch Health Companies Inc. - Vendor overview
Exhibit 55: Bausch Health Companies Inc. - Business segments
Exhibit 56: Bausch Health Companies Inc. - Organizational developments
Exhibit 57: Bausch Health Companies Inc. - Geographic focus
Exhibit 58: Bausch Health Companies Inc. - Segment focus
Exhibit 59: Bausch Health Companies Inc. - Key offerings
Exhibit 60: Bausch Health Companies Inc. - Key customers
Exhibit 61: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 62: Johnson & Johnson Services, Inc. - Business segments
Exhibit 63: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 64: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 65: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 66: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 67: Johnson & Johnson Services, Inc. - Key customers
Exhibit 68: Lupin Ltd. - Vendor overview
Exhibit 69: Lupin Ltd. - Business segments
Exhibit 70: Lupin Ltd. - Organizational developments
Exhibit 71: Lupin Ltd. - Geographic focus
Exhibit 72: Lupin Ltd. - Key offerings
Exhibit 73: Lupin Ltd. - Key customers
Exhibit 74: Merck & Co. Inc. - Vendor overview
Exhibit 75: Merck & Co. Inc. - Business segments
Exhibit 76: Merck & Co. Inc. - Organizational developments
Exhibit 77: Merck & Co. Inc. - Geographic focus
Exhibit 78: Merck & Co. Inc. - Segment focus
Exhibit 79: Merck & Co. Inc. - Key offerings
Exhibit 80: Merck & Co. Inc. - Key customers
Exhibit 81: Mylan NV - Vendor overview
Exhibit 82: Mylan NV - Product segments
Exhibit 83: Mylan NV - Organizational developments
Exhibit 84: Mylan NV - Geographic focus
Exhibit 85: Mylan NV - Segment focus
Exhibit 86: Mylan NV - Key offerings
Exhibit 87: Mylan NV - Key customers
Exhibit 88: Novartis AG - Vendor overview
Exhibit 89: Novartis AG - Business segments
Exhibit 90: Novartis AG - Organizational developments
Exhibit 91: Novartis AG - Geographic focus
Exhibit 92: Novartis AG - Segment focus
Exhibit 93: Novartis AG - Key offerings
Exhibit 94: Novartis AG - Key customers
Exhibit 95: Pfizer Inc. - Vendor overview
Exhibit 96: Pfizer Inc. - Business segments
Exhibit 97: Pfizer Inc. - Organizational developments
Exhibit 98: Pfizer Inc. - Geographic focus
Exhibit 99: Pfizer Inc. - Segment focus
Exhibit 100: Pfizer Inc. - Key offerings
Exhibit 101: Pfizer Inc. - Key customers
Exhibit 102: Sanofi - Vendor overview
Exhibit 103: Sanofi - Business segments
Exhibit 104: Sanofi - Organizational developments
Exhibit 105: Sanofi - Geographic focus
Exhibit 106: Sanofi - Segment focus
Exhibit 107: Sanofi - Key offerings
Exhibit 108: Sanofi - Key customers
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global pulmonary edema therapeutics market: AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing use of biomarkers for disease diagnosis.”

According to the report, one of the major drivers for this market is the high prevalence of risk factors.

Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Johnson & Johnson Services Inc.
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll